| Database ID | Agent | Target | Cancer Type | Detail |
| DB00376 | bevacizumab and erlotinib | NA | head and neck cancer | view |
| DB00377 | nimotuzumab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00378 | nimotuzumab | Epidermal growth factor receptor | Tumors of the nervous system | view |
| DB00379 | nimotuzumab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00380 | nimotuzumab | Epidermal growth factor receptor | esophageal cancer | view |
| DB00381 | lapatinib | Epidermal growth factor receptor
Receptor proteintyrosine kinase erbB2 | head and neck cancer | view |
| DB00382 | lapatinib | Epidermal growth factor receptor
Receptor proteintyrosine kinase erbB2 | head and neck cancer | view |
| DB00383 | lapatinib | Epidermal growth factor receptor
Receptor proteintyrosine kinase erbB2 | head and neck cancer | view |
| DB00384 | lapatinib | Epidermal growth factor receptor
Receptor proteintyrosine kinase erbB2 | head and neck cancer | view |
| DB00385 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | head and neck cancer | view |
| DB00386 | cetuximab and sorafenib | NA | head and neck cancer | view |
| DB00387 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | head and neck cancer | view |
| DB00388 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | head and neck cancer | view |
| DB00389 | erlotinib | Epidermal growth factor receptor | head and neck cancer | view |
| DB00390 | erlotinib | Epidermal growth factor receptor | head and neck cancer | view |